© 2002 by European Society of Cardiology
Copyright © 2002, European Society of Cardiology
Intramyocardial injection of naked DNA encoding HIF-1
/VP16 hybrid to enhance angiogenesis in an acute myocardial infarction model in the rat
aDivision of Cardiology, Shin Kong Wu Ho-Su Memorial Hospital, 95 Wen-Chang Road, Taipei 111, Taiwan
bInstitute of Pharmacology, National Yang Ming University, No. 155, Section 2, Lee-Long Street, Taipei 111, Taiwan
cDepartment of Emergency Medicine, Shin Kong Wu Ho-Su Memorial Hospital, 95 Wen-Chang Road, Taipei 111, Taiwan
* Corresponding author. Tel.: +886-2-2833-2211; fax: +886-2-2836-5775 m001043{at}ms.skh.org.tw
Objectives: The therapeutic utility of hypoxia-inducible factor-1 (HIF-1) transcriptional regulatory system for ischemic hindlimb has been demonstrated. It is not yet known whether this transcriptional regulatory system can be used as a therapeutic strategy to enhance collateral vessel formation in myocardial tissues, where acute hypoxia occurs due to inadequate perfusion. We aimed to test the hypothesis that exogenous administration of HIF-1
/VP16 could enhance collateral vessel formation in a rat acute myocardial infarction model. Methods: Sprague–Dawley rats received ligation of the proximal left anterior descending coronary artery to induce acute myocardial infarction. Immediately after the ligation, 50 µg total plasmid DNA (control, plasmid encoding human vascular endothelial growth factor (pVEGF165), or pHIF-1/VP16) was injected into the infarct area at three locations. Results: Reverse transcription–polymerase chain reaction (RT–PCR) showed the presence of HIF-1 and VEGF mRNA in the myocardium, but not in other organs at days 3 and 7. The infarct size significantly decreased from 37±4% (control) to 24±2% in the VEGF-treated group and 23±2% in the HIF-1/VP16 treated group (P<0.05). Capillary density also significantly increased from 550±75/mm2 (control) to 850±75/mm2 in the VEGF group and 850±50/mm2 in the HIF-1/VP16-treated group (P<0.01). Combined therapy with HIF-1/VP16 and VEGF resulted in higher capillary density (1230±50/mm2) than treatment with either therapy alone. Regional myocardial blood flow was also higher in the treated groups than in the control. Plasma levels of VEGF were also significantly higher in the HIF-1/VP16 and VEGF-treated group than in the control group. Conclusions: The HIF-1/VP16 hybrid transcription factor is able to reduce infarct size and enhance neovascularization in an acute ischemic myocardium. The potency of VEGF and HIF-1/VP16 hybrid as therapeutic angiogenic factors in acute hypoxic myocardium is similar.
KEYWORDS Angiogenesis; Collateral circulation; Gene therapy; Infarction
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. Loinard, A. Ginouves, J. Vilar, C. Cochain, Y. Zouggari, A. Recalde, M. Duriez, B. I. Levy, J. Pouyssegur, E. Berra, et al. Inhibition of Prolyl Hydroxylase Domain Proteins Promotes Therapeutic Revascularization Circulation, July 7, 2009; 120(1): 50 - 59. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Czibik, J. Sagave, V. Martinov, B. Ishaq, M. Sohl, I. Sefland, H. Carlsen, F. Farnebo, R. Blomhoff, and G. Valen Cardioprotection by hypoxia-inducible factor 1 alpha transfection in skeletal muscle is dependent on haem oxygenase activity in mice Cardiovasc Res, April 1, 2009; 82(1): 107 - 114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Zeng, H. Chen, C. Zhu, X. Ren, G. Lin, and F. Cao Effects of combined mesenchymal stem cells and heme oxygenase-1 therapy on cardiac performance Eur. J. Cardiothorac. Surg., October 1, 2008; 34(4): 850 - 856. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M.-C. Lauzier, G. A. Robitaille, D. A. Chan, A. J. Giaccia, and D. E. Richard (2R)-[(4-Biphenylylsulfonyl)amino]-N-hydroxy-3-phenylpropionamide (BiPS), a Matrix Metalloprotease Inhibitor, Is a Novel and Potent Activator of Hypoxia-Inducible Factors Mol. Pharmacol., July 1, 2008; 74(1): 282 - 288. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Kalinowski, L. W. Dobrucki, D. F. Meoli, D. P. Dione, M. M. Sadeghi, J. A. Madri, and A. J. Sinusas Targeted imaging of hypoxia-induced integrin activation in myocardium early after infarction J Appl Physiol, May 1, 2008; 104(5): 1504 - 1512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. C. Wu, F. M. Bengel, and S. S. Gambhir Cardiovascular Molecular Imaging Radiology, August 1, 2007; 244(2): 337 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Reddy, J. C. Osorio, A. M. Duque, B. D. Kaufman, A. B. Phillips, J. M. Chen, J. Quaegebeur, R. S. Mosca, and S. Mital Failure of Right Ventricular Adaptation in Children With Tetralogy of Fallot Circulation, July 4, 2006; 114(1_suppl): I-37 - I-42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Philipp, J. S. Jurgensen, J. Fielitz, W. M. Bernhardt, A. Weidemann, A. Schiche, B. Pilz, R. Dietz, V. Regitz-Zagrosek, K.-U. Eckardt, et al. Stabilization of hypoxia inducible factor rather than modulation of collagen metabolism improves cardiac function after acute myocardial infarction in rats Eur J Heart Fail, June 1, 2006; 8(4): 347 - 354. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Luo, C. Jiang, A. J. Belanger, G. Y. Akita, S. C. Wadsworth, R. J. Gregory, and K. A. Vincent A Constitutively Active Hypoxia-Inducible Factor-1{alpha}/VP16 Hybrid Factor Activates Expression of the Human B-Type Natriuretic Peptide Gene Mol. Pharmacol., June 1, 2006; 69(6): 1953 - 1962. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E. Wilhide and W. K. Jones Potential Therapeutic Gene for the Treatment of Ischemic Disease: Ad2/Hypoxia-Inducible Factor-1{alpha} (HIF-1)/VP16 Enhances B-Type Natriuretic Peptide Gene Expression via a HIF-1-Responsive Element Mol. Pharmacol., June 1, 2006; 69(6): 1773 - 1778. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kido, L. Du, C. C. Sullivan, X. Li, R. Deutsch, S. W. Jamieson, and P. A. Thistlethwaite Hypoxia-Inducible Factor 1-Alpha Reduces Infarction and Attenuates Progression of Cardiac Dysfunction After Myocardial Infarction in the Mouse J. Am. Coll. Cardiol., December 6, 2005; 46(11): 2116 - 2124. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. H. Patel, H. Kimura, C. R. Weiss, G. L. Semenza, and L. V. Hofmann Constitutively active HIF-1{alpha} improves perfusion and arterial remodeling in an endovascular model of limb ischemia Cardiovasc Res, October 1, 2005; 68(1): 144 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Azarnoush, A. Maurel, L. Sebbah, C. Carrion, A. Bissery, C. Mandet, J. Pouly, P. Bruneval, A. A. Hagege, and P. Menasche Enhancement of the functional benefits of skeletal myoblast transplantation by means of coadministration of hypoxia-inducible factor 1{alpha} J. Thorac. Cardiovasc. Surg., July 1, 2005; 130(1): 173 - 179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Heinl-Green, P. W. Radke, F. M. Munkonge, O. Frass, J. Zhu, K. Vincent, D. M. Geddes, and E. W.F.W. Alton The efficacy of a 'master switch gene' HIF-1{alpha} in a porcine model of chronic myocardial ischaemia Eur. Heart J., July 1, 2005; 26(13): 1327 - 1332. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kiji, Y. Dohi, S. Takasawa, H. Okamoto, A. Nonomura, and S. Taniguchi Activation of regenerating gene Reg in rat and human hearts in response to acute stress Am J Physiol Heart Circ Physiol, July 1, 2005; 289(1): H277 - H284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Krombach, J. G. Pfeffer, S. Kinzel, M. Katoh, R. W. Gunther, and A. Buecker MR-guided Percutaneous Intramyocardial Injection with an MR-compatible Catheter: Feasibility and Changes in T1 Values after Injection of Extracellular Contrast Medium in Pigs Radiology, May 1, 2005; 235(2): 487 - 494. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Milkiewicz, C. W Pugh, and S. Egginton Inhibition of endogenous HIF inactivation induces angiogenesis in ischaemic skeletal muscles of mice J. Physiol., October 1, 2004; 560(1): 21 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. L. Semenza Hydroxylation of HIF-1: Oxygen Sensing at the Molecular Level Physiology, August 1, 2004; 19(4): 176 - 182. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. C Chi and J. S Karliner Molecular determinants of responses to myocardial ischemia/reperfusion injury: focus on hypoxia-inducible and heat shock factors Cardiovasc Res, February 15, 2004; 61(3): 437 - 447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. D. Kelly, S. F. Hackett, K. Hirota, Y. Oshima, Z. Cai, S. Berg-Dixon, A. Rowan, Z. Yan, P. A. Campochiaro, and G. L. Semenza Cell Type-Specific Regulation of Angiogenic Growth Factor Gene Expression and Induction of Angiogenesis in Nonischemic Tissue by a Constitutively Active Form of Hypoxia-Inducible Factor 1 Circ. Res., November 28, 2003; 93(11): 1074 - 1081. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Yamakawa, L. X. Liu, T. Date, A. J. Belanger, K. A. Vincent, G. Y. Akita, T. Kuriyama, S. H. Cheng, R. J. Gregory, and C. Jiang Hypoxia-Inducible Factor-1 Mediates Activation of Cultured Vascular Endothelial Cells by Inducing Multiple Angiogenic Factors Circ. Res., October 3, 2003; 93(7): 664 - 673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. E. DUFF, C. LI, J. M. GARLAND, and S. KUMAR CD105 is important for angiogenesis: evidence and potential applications FASEB J, June 1, 2003; 17(9): 984 - 992. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. D. Basson Gut Mucosal Healing : Is the Science Relevant? Am. J. Pathol., October 1, 2002; 161(4): 1101 - 1105. [Full Text] [PDF]
|
|
|
|
 |
|
 J.M. ARBEIT Quiescent Hypervascularity Mediated by Gain of HIF-1{alpha} Function Cold Spring Harb Symp Quant Biol, January 1, 2002; 67(0): 133 - 142. [Abstract] [PDF]
|
|